Literature DB >> 10888772

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

P L Fitzgibbons1, D L Page, D Weaver, A D Thor, D C Allred, G M Clark, S G Ruby, F O'Malley, J F Simpson, J L Connolly, D F Hayes, S B Edge, A Lichter, S J Schnitt.   

Abstract

BACKGROUND: Under the auspices of the College of American Pathologists, a multidisciplinary group of clinicians, pathologists, and statisticians considered prognostic and predictive factors in breast cancer and stratified them into categories reflecting the strength of published evidence.
MATERIALS AND METHODS: Factors were ranked according to previously established College of American Pathologists categorical rankings: category I, factors proven to be of prognostic import and useful in clinical patient management; category II, factors that had been extensively studied biologically and clinically, but whose import remains to be validated in statistically robust studies; and category III, all other factors not sufficiently studied to demonstrate their prognostic value. Factors in categories I and II were considered with respect to variations in methods of analysis, interpretation of findings, reporting of data, and statistical evaluation. For each factor, detailed recommendations for improvement were made. Recommendations were based on the following aims: (1) increasing uniformity and completeness of pathologic evaluation of tumor specimens, (2) enhancing the quality of data collected about existing prognostic factors, and (3) improving patient care. RESULTS AND
CONCLUSIONS: Factors ranked in category I included TNM staging information, histologic grade, histologic type, mitotic figure counts, and hormone receptor status. Category II factors included c-erbB-2 (Her2-neu), proliferation markers, lymphatic and vascular channel invasion, and p53. Factors in category III included DNA ploidy analysis, microvessel density, epidermal growth factor receptor, transforming growth factor-alpha, bcl-2, pS2, and cathepsin D. This report constitutes a detailed outline of the findings and recommendations of the consensus conference group, organized according to structural guidelines as defined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888772     DOI: 10.5858/2000-124-0966-PFIBC

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  230 in total

1.  Extracting functional information from tissues.

Authors:  M P DiGiovanna
Journal:  Mol Diagn       Date:  2001-03

Review 2.  Prognostic factors in breast cancer: current and new predictors of metastasis.

Authors:  D F Hayes; C Isaacs; V Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

Review 3.  Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

4.  Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.

Authors:  Kanwal P S Raghav; Leonel F Hernandez-Aya; Xiudong Lei; Marianan Chavez-Macgregor; Funda Meric-Bernstam; Thomas A Buchholz; Aysegul Sahin; Kim-Anh Do; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-08-11       Impact factor: 6.860

5.  Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer.

Authors:  Amanda L Kong; Welela Tereffe; Kelly K Hunt; Min Yi; Taewoo Kang; Kimberly Weatherspoon; Elizabeth A Mittendorf; Isabelle Bedrosian; Rosa F Hwang; Gildy V Babiera; Thomas A Buchholz; Funda Meric-Bernstam
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

6.  TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).

Authors:  Ilaria Muller; Lucy S Kilburn; Peter N Taylor; Peter J Barrett-Lee; Judith M Bliss; Paul Ellis; Marian E Ludgate; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2017-04-04

7.  Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course.

Authors:  Paweł Surowiak; Piotr Dziegiel; Rafał Matkowski; Mirosław Sopel; Andrzej Wojnar; Jan Kornafel; Maciej Zabel
Journal:  Virchows Arch       Date:  2003-01-25       Impact factor: 4.064

8.  Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast.

Authors:  Andrew J Creager; Kim R Geisinger; Nancy D Perrier; Perry Shen; Jo Ann Shaw; Peter R Young; Doug Case; Edward A Levine
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

9.  Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer.

Authors:  E Fiore; E Giustarini; C Mammoli; F Fragomeni; D Campani; I Muller; A Pinchera; C Giani
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

10.  Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer.

Authors:  Elizabeth A Mittendorf; Karla V Ballman; Linda M McCall; Min Yi; Aysegul A Sahin; Isabelle Bedrosian; Nora Hansen; Sheryl Gabram; Thelma Hurd; Armando E Giuliano; Kelly K Hunt
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.